Krebs Biochemicals & Industries Limited (KREBSBIO.NS)
INR 73.54
(1.56%)
INR 73.54
(1.56%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.93 Billion INR | 5.54% |
| 2022 | 1.83 Billion INR | 215.41% |
| 2021 | 580.67 Million INR | -41.84% |
| 2020 | 998.35 Million INR | 23.02% |
| 2019 | 811.56 Million INR | 5.48% |
| 2018 | 769.36 Million INR | -15.9% |
| 2017 | 914.8 Million INR | 92.87% |
| 2016 | 474.3 Million INR | -37.01% |
| 2015 | 753 Million INR | 396.6% |
| 2014 | 151.63 Million INR | 0.0% |
| 2012 | 922.95 Million INR | 16.1% |
| 2011 | 794.94 Million INR | -7.33% |
| 2010 | 857.82 Million INR | -0.5% |
| 2009 | 862.13 Million INR | 4.81% |
| 2008 | 822.54 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | 858 Thousand INR | -99.95% |
| 2023 FY | 1.93 Billion INR | 5.54% |
| 2023 Q2 | 1.87 Billion INR | 218713.87% |
| 2023 Q4 | 1.93 Billion INR | 246760.92% |
| 2023 Q3 | 783 Thousand INR | -99.96% |
| 2022 Q3 | 874 Thousand INR | -99.95% |
| 2022 Q4 | 1.83 Billion INR | 209455.03% |
| 2022 Q1 | 1 Million INR | -99.83% |
| 2022 FY | 1.83 Billion INR | 215.41% |
| 2022 Q2 | 1.73 Billion INR | 172478.33% |
| 2021 Q4 | 580.67 Million INR | 37386.77% |
| 2021 Q1 | 7.1 Million INR | -99.29% |
| 2021 FY | 580.67 Million INR | -41.84% |
| 2021 Q2 | 1.22 Billion INR | 17162.39% |
| 2021 Q3 | 1.54 Million INR | -99.87% |
| 2020 FY | 998.35 Million INR | 23.02% |
| 2020 Q2 | 816.48 Million INR | 31793.79% |
| 2020 Q3 | 2.65 Million INR | -99.67% |
| 2020 Q1 | 2.56 Million INR | -99.68% |
| 2020 Q4 | 998.35 Million INR | 37446.33% |
| 2019 Q4 | 811.56 Million INR | 4128.23% |
| 2019 FY | 811.56 Million INR | 5.48% |
| 2019 Q2 | 499.15 Million INR | 180.22% |
| 2019 Q3 | 19.19 Million INR | -96.15% |
| 2019 Q1 | 178.13 Million INR | -76.85% |
| 2018 Q2 | 509 Million INR | -9.62% |
| 2018 Q1 | 563.2 Million INR | 9.91% |
| 2018 FY | 769.36 Million INR | -15.9% |
| 2018 Q4 | 769.36 Million INR | 26540.17% |
| 2018 Q3 | 2.88 Million INR | -99.43% |
| 2017 Q2 | 512 Million INR | 43623.65% |
| 2017 Q4 | 512.43 Million INR | 20892.75% |
| 2017 Q1 | 1.17 Million INR | -99.73% |
| 2017 FY | 914.8 Million INR | 92.87% |
| 2017 Q3 | 2.44 Million INR | -99.52% |
| 2016 Q4 | 426.7 Million INR | 10963.08% |
| 2016 FY | 474.3 Million INR | -37.01% |
| 2016 Q3 | 3.85 Million INR | -99.51% |
| 2016 Q2 | 790.38 Million INR | 29381.13% |
| 2016 Q1 | 2.68 Million INR | -99.64% |
| 2015 Q1 | 63.09 Million INR | -88.45% |
| 2015 FY | 753 Million INR | 396.6% |
| 2015 Q4 | 753 Million INR | 21962.97% |
| 2015 Q3 | 3.41 Million INR | -99.48% |
| 2015 Q2 | 653.05 Million INR | 935.06% |
| 2014 Q4 | 546.03 Million INR | 0.0% |
| 2014 Q1 | 3.56 Million INR | 9.91% |
| 2014 FY | 151.63 Million INR | 0.0% |
| 2013 Q2 | 922.95 Million INR | 0.0% |
| 2013 Q4 | 3.24 Million INR | -98.79% |
| 2013 Q3 | 267.54 Million INR | -71.01% |
| 2012 FY | 922.95 Million INR | 16.1% |
| 2012 Q2 | 871.7 Million INR | 0.0% |
| 2011 Q4 | 794.94 Million INR | 0.0% |
| 2011 FY | 794.94 Million INR | -7.33% |
| 2010 FY | 857.82 Million INR | -0.5% |
| 2009 FY | 862.13 Million INR | 4.81% |
| 2008 FY | 822.54 Million INR | 0.0% |
| 2008 Q4 | 822.54 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 50.001% |
| Hester Biosciences Limited | 2.29 Billion INR | 15.62% |
| Aarti Drugs Limited | 5.54 Billion INR | 65.163% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 25.996% |
| Albert David Limited | -278.36 Million INR | 794.374% |
| Alembic Limited | 66.9 Million INR | -2789.269% |
| Alkem Laboratories Limited | -1.6 Billion INR | 220.102% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | -740.645% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 41.408% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 10578.808% |
| Brooks Laboratories Limited | 49.48 Million INR | -3806.075% |
| Eris Lifesciences Limited | 13.8 Billion INR | 86.0% |
| FDC Limited | -57.75 Million INR | 3446.933% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 167.997% |
| Gufic Biosciences Limited | 3.19 Billion INR | 39.489% |
| Hikal Limited | 7.96 Billion INR | 75.738% |
| Ind-Swift Limited | 9.5 Billion INR | 79.672% |
| Innova Captab Limited | 2.33 Billion INR | 17.176% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 275.513% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 239.066% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 92.86% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | 1614.377% |
| Lupin Limited | 19.38 Billion INR | 90.029% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -98.084% |
| Medico Remedies Limited | 78.67 Million INR | -2356.78% |
| Morepen Laboratories Limited | -231.17 Million INR | 936.133% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 68.608% |
| Orchid Pharma Limited | -1.31 Billion INR | 247.119% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 182.322% |
| RPG Life Sciences Limited | -364.7 Million INR | 630.003% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -1510.244% |
| Sigachi Industries Limited | 859.94 Million INR | -124.772% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 80.732% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -1233.27% |
| Themis Medicare Limited | 764.96 Million INR | -152.682% |
| Unichem Laboratories Limited | 931.91 Million INR | -107.414% |
| Vaishali Pharma Limited | 119.13 Million INR | -1522.463% |
| Wanbury Limited | 1.1 Billion INR | -74.787% |
| Windlas Biotech Limited | -273.04 Million INR | 807.926% |
| ZIM Laboratories Limited | 983.6 Million INR | -96.514% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 146.542% |
| Ipca Laboratories Limited | 11.41 Billion INR | 83.067% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 102.667% |
| Venus Remedies Limited | -267.7 Million INR | 822.047% |
| Sakar Healthcare Limited | 790.93 Million INR | -144.384% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 47.664% |
| Divi's Laboratories Limited | -39.77 Billion INR | 104.86% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 138.562% |
| Mankind Pharma Limited | -1.74 Billion INR | 210.557% |
| Sequent Scientific Limited | 4.17 Billion INR | 53.743% |
| Laurus Labs Limited | 24.35 Billion INR | 92.064% |
| Neuland Laboratories Limited | -214.05 Million INR | 1002.989% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 31.486% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 145.106% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 50.59% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 876.922% |
| Wockhardt Limited | 18.27 Billion INR | 89.42% |
| Bal Pharma Limited | 1.26 Billion INR | -52.974% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 85.031% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 266.955% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | 627.344% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 135.095% |
| Shilpa Medicare Limited | 9.06 Billion INR | 78.688% |
| Valiant Laboratories Limited | 649.9 Million INR | -197.417% |
| Ajanta Pharma Limited | -954.9 Million INR | 302.421% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | -549.548% |
| Granules India Limited | 9.28 Billion INR | 79.186% |
| Medicamen Biotech Limited | 160.31 Million INR | -1105.694% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -4082.816% |
| Piramal Enterprises Limited | 491.39 Billion INR | 99.607% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 93.927% |
| NATCO Pharma Limited | -5.81 Billion INR | 133.229% |
| Suven Life Sciences Limited | -1.63 Billion INR | 218.388% |
| Strides Pharma Science Limited | 23.25 Billion INR | 91.689% |
| Indoco Remedies Limited | 6.47 Billion INR | 70.154% |
| Alpa Laboratories Limited | 35.36 Million INR | -5365.942% |
| Lasa Supergenerics Limited | 205.79 Million INR | -839.228% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 305.237% |